(Q39154839)

9 September 2017

title

Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection (English)

1 reference

9 September 2017

5

Gerd Fätkenheuer

1 reference

9 September 2017

Tim Kümmerle

1

1 reference

9 September 2017

Clara Lehmann

series ordinal

2

1 reference

9 September 2017

Pia Hartmann

series ordinal

3

1 reference

9 September 2017

Christoph Wyen

series ordinal

4

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Investigational Drugs

9 September 2017

published in

1 reference

9 September 2017

volume

18

1 reference

9 September 2017

issue

11

1 reference

9 September 2017

page(s)

1773-1785

1 reference

Estimation of HIV incidence in the United States

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Biology of CCR5 and its role in HIV infection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

HIV and the chemokine system: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Drug interactions with new and investigational antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357478

10.1517/13543780903357478

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference